Chemomab Therapeutics (CMMB) Capital Expenditures (2018 - 2023)
Chemomab Therapeutics posted quarterly Capital Expenditures of $6000.0 for Q4 2023, down 95.56% year-on-year from $135000.0 in Q4 2022, and up 250.0% on a QoQ basis from -$4000.0 in Q2 2023.
Chemomab Therapeutics (CMMB) has 6 years of Capital Expenditures data on file, last reported at $6000.0 in Q4 2023.
- For the quarter ending Q4 2023, Capital Expenditures fell 95.56% year-over-year to $6000.0; the trailing twelve-month figure through Dec 2023 stood at $3000.0 (down 95.59% YoY), and the FY2025 full-year result was $3000.0, changed N/A from the prior year.
- Capital Expenditures for Q4 2023 stood at $6000.0, up from -$4000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $255000.0 in Q3 2019 and bottomed at -$251000.0 in Q4 2019.
- The 5-year median for Capital Expenditures is $8500.0 (2020), against an average of $24611.1.
- The widest annual swing landed in 2019, when Capital Expenditures slumped 162.75%; it then surged 13300.0% in 2021.
- A 5-year view of Capital Expenditures shows it stood at -$251000.0 in 2019, then jumped by 100.4% to $1000.0 in 2020, then soared by 13300.0% to $134000.0 in 2021, then rose by 0.75% to $135000.0 in 2022, then plunged by 95.56% to $6000.0 in 2023.
- The last three Capital Expenditures figures came in at $6000.0 (Q4 2023), -$4000.0 (Q2 2023), and $1000.0 (Q1 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 135,000.00 |
| Dec 31, 2022 | 135,000.00 |
| Sep 30, 2022 | -42,000.00 |
| Sep 30, 2022 | -42,000.00 |
| Jun 30, 2022 | -39,000.00 |
| Jun 30, 2022 | -39,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 134,000.00 |
| Dec 31, 2021 | 134,000.00 |
| Jun 30, 2021 | 102,000.00 |
| Jun 30, 2021 | 102,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 20,000.00 |
| Sep 30, 2020 | 20,000.00 |
| Jun 30, 2020 | 7,000.00 |
| Jun 30, 2020 | 7,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Dec 31, 2019 | -251,000.00 |
| Dec 31, 2019 | -251,000.00 |
| Sep 30, 2019 | 255,000.00 |
| Sep 30, 2019 | 255,000.00 |
| Jun 30, 2019 | 16,000.00 |
| Jun 30, 2019 | 16,000.00 |
| Mar 31, 2019 | 75,000.00 |
| Mar 31, 2019 | 75,000.00 |
| Dec 31, 2018 | 400,000.00 |
| Dec 31, 2018 | 400,000.00 |
| Sep 30, 2018 | -89,000.00 |
| Sep 30, 2018 | -89,000.00 |